Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework-Reference-Cited by-同舟云学术

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework

Published:2018-11 Issue:11 Volume:56 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Oštrbenk Anja¹,Xu Lan²,Arbyn Marc²,Poljak Mario¹^ORCID

Affiliation:

1. Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

2. Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium

Abstract

In 2012, VALidation of human papillomavirus (HPV) GENotyping Tests (VALGENT) was initiated to provide a formalized and uniform study framework for comparison and validation of HPV assays with genotyping capability. In VALGENT-3, the clinical and analytical performance of Anyplex II HPV HR detection (Anyplex) was compared to that of the Hybrid Capture 2 HPV DNA test (hc2) and the cobas 4800 HPV test (cobas).

Funder

European Commission

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01176-18

Reference46 articles.

1. Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test

2. Human Papillomavirus Oncogenic mRNA Testing for Cervical Cancer Screening

3. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials